June 30, 2025 4:36pm

Referencing the pre-open’s title, “the sword of Damocles hangs” …

Consider your portfolio’s “six,” share pricing contractions are coming

Love the highs, almost time to cry as Q2 comes to an end and earnings season evolves; unless you do or don’t say bye to some holdings

I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed! 

 

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key sector-moving events and distill that into a cogent outlook.

 

Friday’s RegMed Investors’ (RMi) pre-open: the sword of Damocles hangs … https://www.regmedinvestors.com/articles/13979

Friday night’s RegMed Investors (RMi) Closing Bell: Econ’s inflation data was hotter than expected as May PCE pushes rate cuts odds lower … https://www.regmedinvestors.com/articles/13978

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed UP +275.50 points or +0.63%, the S&P closed UP +31.88 points or +0.52% while the Nasdaq closed UP +96.28 points or +0.48%

  • Theme of the session, close-out June and wrap-up Q2
  • This month, the S&P 500 is up more than 4%, the Nasdaq has jumped more than 6% and the Dow has added about 4% to date.

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

Monday’s advance/decline line opened positive with 27 incliners, 4 decliners and 4 flats ending with a positive close of 20 incliners, 11 decliners and 4 flats  

Metrics:  Monday, the IBB was up +0.04%, the XBI was down -0.08% while the VIX was up +0.41points or +2.51% at 16.73

 

Q2/25 – June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Monday Closing UP (10 of 20) +$ after Friday’s

  • Alnylam Pharmaceuticals (ALNY +$3.26 after Friday’s +$4.58
  • CRISPR Therapeutics (CRSP +$1.15 after Friday’s +$0.79
  • Vericel (VCEL +$0.82 after Friday’s +$0.07),
  • Moderna (MRNA +$0.43 after Friday’s -$0.38).
  • AxoGen (AXGN +$0.35 after Friday’s +$0.03),
  • Beam Therapeutics (BEAM +$0.21 after Friday’s -$0.34
  • MiMedx (MDXG +$0.17 after Friday’s $0.00),
  • Solid Biosciences (SLDB +$0.15 after Friday’s -$0.09)
  • Voyager Therapeutics (VYGR +$0.15),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.10 with 8100 shares traded - ??)

Flat (4)

  • bluebird bio (BLUE) P/E acquired
  • Caribou Bioscience (CRBU)
  • Homology Medicine (FIXX)
  • Precigen (PGEN)

Monday’s Closing DOWN (11 of 11): -$ after Friday’s

  • Lenz Therapeutics (LENZ -$0.87 after Friday’s +$0.07),
  • Ionis Pharmaceuticals (IONS -$0.29 after Friday’s +$0.02
  • Agenus (AGEN -$0.19 after Friday’s -$0.15),
  • Regenxbio (RGNX -$0.18 after Friday’s -$0.36),
  • Intellia Therapeutics (NTLA -$0.18),
  • Adverum Biotechnologies (ADVM -$0.17 after Friday’s -$0.17),
  • Ultragenyx Pharmaceuticals (RARE -$0.16 after Friday’s -$0.60
  • Editas Medicine (EDIT -$0.08 after Friday’s +$0.16),
  • Verve Therapeutics (VERV -$0.07 after Friday’s +$0.05),
  • Sage Therapeutics (SAGE -$0.03 after Friday’s -$0.13),

 

The BOTTOM LINE:  Last session Monday … a positive end to June and Q2/25

Last week <6/23 to 6/27> opens with a barely Monday negative close followed by a Tuesday positive close and a barely negative close on Wednesday and Thursday… followed by another down turn in negative territory on Friday

The previous week, 6/16 – 6/20 started with a Monday positive close … followed by Tuesday’s negative close … and a Wednesday’s positive close, Thursday’s market holiday and Friday’s negative close.

  • The week of 6/9 – 6/13; Friday, the cell and gene therapy sector stayed in negative territory following Thursday's trading session ended with a negative territory, after May's Producer Price Index (PPI) report following Wednesday's negative close after May's Consumer Price Index (CPI) report post Monday’s neutral close.
  • The cell and gene therapy sector popped Friday after Thursday’s reverses on Thursday from a negative open with a barely positive close after Wednesday’s positive close – although slipping
  • Following upsides on Tuesday and Monday) after its “napping and waking” in the May share pricing doldrums initiated by a sweetener of BPMC getting an acquired by BMY, MRNA regulatory approval and BNTX’s partnership with BMY.

 

Interesting … Sam Stoval Sam Stovall, chief investment strategist at CFRA Research speaks/writes:

  • “No one could fault an investor if at one point during the first half of 2025 they shouted, ‘Stop the world, I want to get off,’”. “Indeed, 33% of all trading days experienced volatility of 1% or more, versus the 10-year average of 25%, and almost reaching 50% of all days from the peak on February 19 through the end of the near-19% correction on April 8.”
  • The S&P 500 is due for further gains now that it’s surpassed that challenge, Stovall said. The strategist said the broad market index could climb another 6% to 10%, based on similar scenarios across market history, so long as it survives a seasonally challenge.

 

As I also wrote, about June… Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • Although historically, June (in the past) has been a slow or weak month – I/we just saw a tremendous start (6/2) with partnership, acquisition, and regulatory news 
  • Also, ASCO opens this month with probably a lot of news flow attracting attention of funds such as hedges and electronic traders.

There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

June ‘25: understand the “flow” …

  • 6/30 - Monday closed positive with 20 positive, 11 negative and 4 flats
  • 6/27 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 6/26 - Thursday closed negative with 14 positive, 18 negative and 3 flats
  • 6/25 - Wednesday closed negative with 14 positive, 17 negative and 4 flats
  • 6/24 - Tuesday closed positive with 30 positive, 3 negative and 2 flats
  • 6/23 - Monday closed negative with 15 positive, 16 negative and 4 flats
  • 6/20 - Friday closed negative with 14 positive, 18 negative and 3 flats
  • 6/19 – Thursday was a market holiday
  • 6/18 – Wednesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/17 - Tuesday closed negative with 10 positive, 23 negative and 2 flats
  • 6/16 - Monday closed positive with 20 positive, 11 negative and 4 flats
  • 6/13 - Friday closed negative with 5 positive, 25 negative and 5 flats
  • 6/12 – Thursday closed negative with 7 positive, 23 negative and 5 flats
  • 6/11 - Wednesday closed negative with 6 positive, 25 negative and 4 flats
  • 6/10 – Tuesday closed positive with 17 positive, 15 negative and 3 flats
  • 6/9 – Monday closed neutral with 16 positive, 16 negative and 3 flats
  • 6/6 – Friday closed positive with 28 positive, 4 negative and 3 flats
  • 6/5 – Thursday closed positive with 16 positive, 15 negative and 4 flats
  • 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
  • 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
  • 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Vericel (VCEL)
  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Mesoblast (MESO)

The worst three (3) in the session: 

  • Monday: Lenz Therapeutics (LENZ), Ionis Pharmaceuticals (IONS) and Agenus (AGEN)
  • Friday: Ultragenyx Pharmaceuticals (RARE), Moderna (MRNA) and UniQure NV (QURE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.